New research reveals that individuals who discontinue blockbuster slimming jabs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who end conventional diet and exercise programs.
Research printed in a prominent health publication shows that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the mass comes back at an estimated rate of nearly a kilo each month once they quit.
"People purchasing such drugs should be informed of the risk of fast rebound weight gain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain suggests a return to original weight within about a year and a half.
Analyzing Therapies
The study, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through diet and exercise usually experience a less rapid creep back—perhaps 100 grams monthly—once they finish.
Understanding the Fast Regain
Experts believe the mechanism of the injections is key to understanding the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for people with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals say that, due to the high risk of relapse, the treatment might need to be ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," similar to managing diseases like diabetes.
User Testimonies
People who have discontinued the medication explain a intense resurgence of appetite.
"I experienced something flipping and you become starving," described a patient.
This challenge is worsened if patients have not developed permanent dietary or behavioural modifications during treatment.
Growing Interest
Figures indicate that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is higher among females than men.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent solution and maintained weight loss relies on combined behavioural changes.
